...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
Reply New Message
Back To Forum List View
Icon president New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
3
BearDownAZ
Mar 02, 2017 10:51AM
Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
6
coldnewfie
Mar 02, 2017 06:54PM
Icon president Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
4
SanFrancisco99
Mar 02, 2017 10:43PM
Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
4
Nextblockbuster
Mar 03, 2017 10:01AM
Icon president Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
3
SanFrancisco99
Mar 03, 2017 10:14AM
Icon president Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
3
BearDownAZ
Mar 03, 2017 10:20AM

Bear,

So far to date the trial began in June 2016 almost 9 months ago and if there were safety issues I would think they would have stopped the trial?  They have a dose escalated trial 3 + 3 i think with no safety isssues to date. So why your concern with safety with 3694, Are you thing 1 to 2 years out there could be safety issues??

2 Recommendations
Icon president Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
5
BearDownAZ
Mar 03, 2017 01:10PM
Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
3
Nextblockbuster
Mar 03, 2017 01:25PM
Icon president Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
3
BearDownAZ
Mar 03, 2017 02:07PM
Reply New Message
Back To Forum List View
Share
Share
New Message
Please login to post a reply